ライフサイエンスコーパス: E coli

1 lates (2301 [85%] K pneumoniae and 402 (15%) E coli).

2 in response to serum-opsonized S aureus and E coli.

3 o produce IL-10 in response to adenosine and E coli.

4 gene arrangement pattern similar to that in E coli.

5 terial gel overlay against S epidermidis and E coli.

6 al critical step in the host defense against E coli.

7 with IAV markedly increased phagocytosis of E coli.

8 well as hemostatic system responses to LD100 E coli.

9 the inflammatory cytokine response to LD100 E coli.

10 e-to-susceptibility phenotype predictions in E coli.

11 d could subsequently be reconjugated back to E coli.

12 L chromogenic agar to isolate ESBL-producing E coli.

13 outcome was colonisation with ESBL-producing E coli.

14 are due to gram-negative organisms, such as E coli.

15 njugants and its ability to transfer back to E coli.

16 hich 152 samples from 97 (65%) patients grew E coli.

17 teriuria caused by fluoroquinolone-resistant E coli.

18 l ulcer, which was culture positive for ESBL E coli.

19 HEp2 cells and (2) killing of intracellular E coli.

20 dly attenuated when the gene is deleted from E coli.

21 cteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized an

22 ; difference 7.1%, 95% CI 2.2-10.8, p=0.005; E coli: 3/211, 1%, difference 4.3%, 1.5-5.9, p=0.003).

23 coccus aureus (652, 10%), GBS (326, 5%), and E coli (319, 5%).

24 Of the E coli, 85.0% carried a bla(CTX-M) variant, while 81.8%

25 Isolation from stool was most common with E coli (87.0%) followed by K pneumoniae (62.5%).

26 s were treated with both IAV and unopsonized E coli, a marked enhancement of the rate and extent of n

27 control baboons were also infused with LD100 E coli alone and followed as described above.

28 aneous treatment of neutrophils with IAV and E coli also elicited greater hydrogen peroxide productio

29 ESBL-E coli also were frequent in sewage and retail chicken (

30 Eight baboons infused for 2 hours with LD100 E coli also were given five bolus infusions of DEGR VIIa

31 nce of antibiotic susceptibility patterns of E coli among infants admitted to neonatal intensive care

32 with apparent transmission of NDM-producing E coli among patients at 1 hospital.

33 nd/or attenuates the lethal effects of LD100 E coli and (2) whether these effects are accompanied by

34 promoter-luciferase construct indicated that E coli and adenosine synergistically activate IL-10 tran

35 alence of resistance from 1992 to 1996 among E coli and all isolates combined to ampicillin (P<.002),

36 The prevalence of resistance among E coli and all isolates combined was more than 20% for a

37 This work highlights a scale of E coli and antimicrobial-resistant organism acquisition

38 d to detect and characterise transmission of E coli and associated plasmids in a hospital setting.

39 ctively screened fecal metagenomes for pks(+)E coli and compared the presence of pks in patients befo

40 baboons administered a two-hour infusion of E coli and followed for a maximum of 28 days.

41 SBL-containing multiple antibiotic-resistant E coli and K pneumoniae.

42 The prevalence of mcr-1 was investigated in E coli and Klebsiella pneumoniae strains collected from

43 ng determined the presence of ESBL-producing E coli and Klebsiella pneumoniae, and hierarchical logis

44 profloxacin hydrochloride was 0% to 2% among E coli and less than 10% among all isolates combined, an

45 eptible clinical isolates of K pneumoniae or E coli and ten susceptible same-species comparator isola

46 e coagulopathic and inflammatory response to E coli and that EPCR provides an additional critical ste

47 an 9% in 1992 to more than 18% in 1996 among E coli, and from 8% to 16% among all isolates combined.

48 , rotavirus, Shigella spp and enteroinvasive E coli, and Vibrio cholerae-the strength of association

49 = .03) when challenged with enteropathogenic E coli, and were protected from immune infiltration, cry

50 rees C) and an etiologic organism other than E coli are at high risk for the development of renal sca

51 Using E coli as a model, we show that m(1)G37 deficiency induc

52 er p 2/1S were expressed in large amounts in E coli as soluble and folded proteins.

53 Asparaginase levels and antibody to both E coli asparaginase and PEG-asp were measured weekly jus

54 Use of native E coli asparaginase in induction leads to high hypersens

55 s) in intensification after receiving native E coli asparaginase in induction.

56 ations are depleted by conventional doses of E coli asparaginase in the majority of patients, but the

57 Using the double-labeled E coli assay, HPC was decreased in all transplanted anim

58 no effect on the peak TNF response to LD100 E coli at T = 2 hours (170 +/- 32 v 120 +/- 35 ng/mL).

59 th albumin) or an adenovirus encoding either E coli beta-galactosidase (Ad.CMVLacZ, viral control; 10

60 INTERPRETATION: This tetravalent E coli bioconjugate vaccine candidate was well tolerated

61 E coli BL21 and E coli BL21_HTW were gavaged to ovalbumi

62 The Escherichia coli BL21 (E coli BL21) strain was genetically modified to express

63 E coli BL21 and E coli BL21_HTW were gavaged to ovalbumin (OVA) sensitiz

64 ella morganii (M morganii)-derived HDC gene (E coli BL21_HTW).

65 Oral administration of E coli BL21_HTW, which is able to secrete histamine, to

66 We sequenced all the available E coli bloodstream infection isolates provided by the Br

67 Seven patients developed E coli bloodstream infection, four with identical strain

68 hort study that sampled isolates from 22 512 E coli bloodstream infections included in the Norwegian

69 acteristics and prognosis of 770 episodes of E coli BSI were analyzed and isolates sequenced (Illumin

70 used in case of clinical hypersensitivity to E coli but not for subclinical development of antibodies

71 C, Cryptosporidium, typical enteropathogenic E coli) can substantially reduce the burden of moderate-

72 resistant phenotypes and multidrug-resistant E coli carriage in urban wildlife is linked to variation

73 se-producing Escherichia coli isolates (ESBL-E coli) cause more than 5000 cases of bacteraemias annua

74 Here, we show how live E coli cell PCR and one-step LiCl-isopropanol purificati

75 Conversely, only E coli challenge activated the complement system, reachi

76 sequestration and vascular injury induced by E coli challenge.

77 y effect of adenosine on IL-10 production by E coli-challenged macrophages, whereas A(2B) receptors h

78 h these bacteria compared with nonpathogenic E coli; chitinase activities were measured using the col

79 stributed across clades, we identified three E coli clades (ST410, ST617, and ST648) that were isolat

80 ess of widely disseminated MDR ESBL-carrying E coli clones.

81 rlapping clusters, suggesting ESBL-producing E coli co-circulation both within and between compartmen

82 to a farm was associated with mcr-1-negative E coli colonisation (p=0.03, univariate test).

83 models illustrated that human ESBL-producing E coli colonisation was associated with the wet season (

84 mpared with 378 patients with mcr-1-negative E coli colonisation, whereas living next to a farm was a

85 f women in the cefpodoxime group had vaginal E coli colonization.

86 Uropathogenic E coli containing prsG-adhesin-encoding plasmids aggluti

87 typically involve growing Escherichia coli (E coli) containing plasmids, followed by plasmid DNA ext

88 Each dose of a pegylated E coli-derived asparaginase remaining in patients' treat

89 eceiving blocking mAb to EPCR plus sublethal E coli died 7 to 54 hours after challenge, whereas all a

90 t strain types of resistant K pneumoniae and E coli distributed among the nursing homes.

91 cularly after intracolonic administration of E coli DNA.

92 We mixed this recipient community with the E coli donor strain carrying the gfp-tagged plasmid, bot

93 istration of lysozyme prevented expansion of E coli during maternal separation and visceral hypersens

94 anges in annual antibiotic susceptibility of E coli during the study period.

95 at 67% of travellers acquired new strains of E coli during travel that were phylogenetically distinct

96 impaired their bactericidal activity against E coli, E faecalis, and S typhimurium, whereas exposure

97 t combination of EHEC- and enteroaggregative E coli (EAEC)-specific virulence factors.

98 ia coli O104:H4 caused the enterohemorrhagic E coli (EHEC) outbreak with the highest incidence rate o

99 rsus 0.1 (24-59 months); for enterotoxigenic E coli encoding heat-stable toxin was 4.2 versus 0.1 (0-

100 pathogenic Escherichia coli, enterotoxigenic E coli encoding heat-stable toxin, enteroaggregative E c

101 tive efficacy in children in enterotoxigenic E coli-endemic areas.

102 of 29 915 men had fluoroquinolone-resistant E coli events.

103 issues from animals receiving only sublethal E coli exhibited none of these abnormal histopathologic

104 tion of invasive extra-intestinal pathogenic E coli (ExPEC) disease.

105 E coli-expressed purified domain I selectively bound IgG

106 x2 are more likely to cause D(+)HUS than are E coli expressing only Stx1.

107 The validation of MM-PBSA for the E coli FabI system serves as a platform for inhibitor de

108 ce, has not been previously observed in ESBL E coli from any infection site.

109 SI isolates were compared with 362 commensal E coli from healthy subjects.

110 Sequence type (ST) 131 dominated among ESBL-E coli from human blood (188 [64%] of 293 isolates), fae

111 at shock proteins IbpA and IbpB that protect E coli from oxidative stress, compared to healthy, wild-

112 to ciprofloxacin rose from 2.5% to 31.1% in E coli, from 1.7% to 70.2% in Klebsiella spp and from 5.

113 We also found that nonpathogenic E coli gain degrading activity when they are forced to e

114 Analysis of the E coli genome showed it to belong to multilocus sequence

115 300 105 events with E coli growth and 1 899 168 cultures with no growth were

116 istant, and primary ocular infection by ESBL E coli has rarely been reported.

117 lin G antibodies, but not anti-human or anti-E coli homologs, was independently associated with CAD.

118 1.9; 0.99-3.5) and typical enteropathogenic E coli (HR 2.6; 1.6-4.1) in infants aged 0-11 months, an

119 es from patients with IBS, larger numbers of E coli HS and S typhimurium passed through the epitheliu

120 P= 0.001, OR 3.9), cHsp10 (P=0.045, OR 3.8), E coli Hsp60 (P=0.04, OR 1.5) and C pneumoniae (P=0.03,

121 clinically relevant antimicrobial-resistant E coli in Nairobi, exhibiting resistance to drugs consid

122 of 9 cases) or clearance (13 of 18) of pks(+)E coli in pks(+) patients was correlated to pks in the d

123 We used selective media to seek ESBL-E coli in routinely submitted samples from human faeces,

124 Most human bacteraemias with ESBL-E coli in the UK involve internationally prevalent human

125 notypic diversity of antimicrobial-resistant E coli in wildlife was lower than in livestock, humans,

126 group 2 pathogens, particularly S aureus and E coli, in otherwise unexplained cases of SUDI suggests

127 ion in platelets coincubated with pathogenic E coli including alpha-hemolysin producing strains.

128 f 20 243 human faeces samples contained ESBL-E coli, including 678 (17%) of 3995 in London.

129 7%) of 1131 samples contained mcr-1-positive E coli, including wild bird droppings (25 [25%] of 100),

130 gene, but not chiA from nonpathogenic (K12) E coli, increased adhesion.

131 onal C3H/HeN adult mice with 10(9) commensal E coli induced visceral hypersensitivity.

132 The stimulatory effect of adenosine on E coli-induced IL-10 production did not require toll-lik

133 e for the stimulatory effect of adenosine on E coli-induced IL-10 promoter activity.

134 Adenosine augmented E coli-induced nuclear accumulation and DNA binding of C

135 ter characteristics associated with neonatal E coli infection and antibiotic susceptibility were asse

136 ]) from 69 centers had at least 1 episode of E coli infection and available susceptibility results.

137 721 infants (434 male [60.2%]; median age at E coli infection, 14 days [interquartile range, 1-33 day

138 py is widely used to treat enteroaggregative E coli infection.

139 olates and a random sample of mcr-1-negative E coli infections from the retrospective collection betw

140 Developing interventions to reduce E coli infections requires an understanding of the frequ

141 eit with different timing, both FXa/PCPS and E coli infusion led to robust thrombin and plasmin gener

142 r the pks abundance and persistence of pks(+)E coli is influenced by pks status of the donor feces.

143 , the antimicrobial effect of PGRP-S against E coli is synergistic with lysozyme, and lysozyme and PG

144 that donor-to-patient transmission of pks(+)E coli is unlikely.

145 January 1, 2009, to December 31, 2017, with E coli isolated from blood, cerebrospinal fluid, or urin

146 Strains of E coli isolated from community urine samples from Januar

147 or intermediate for 89.2% of ESBL-producing E coli isolates (569/638 isolates) and 67.7% of ESBL-pro

148 We sequenced multiple E coli isolates (both extended spectrum B-lactamase [ESB

149 tudy, we included 76 mcr-1-positive clinical E coli isolates and 508 mcr-1-negative isolates.

150 We observed mcr-1 carriage in E coli isolates collected from 78 (15%) of 523 samples o

151 thromycin resistance was common in commensal E coli isolates from enrolled children before randomisat

152 We sequenced whole genomes of ESBL-producing E coli isolates from humans, animals, and the environmen

153 odstream and 83 veterinary surveillance ESBL-E coli isolates from the same regions.

154 Among 444 281 E coli isolates from urine samples tested in 1013 labora

155 We evaluated 2875 E coli isolates obtained during 2013-2018 and 2020.

156 Wildlife carried a low prevalence of E coli isolates susceptible to all antibiotics tested (4

157 ESBL-producing E coli isolates underwent whole-genome sequencing.

158 vational study, we evaluated a collection of E coli isolates with linked whole-genome sequencing and

159 ction, mcr-1 was detected in 76 (1%) of 5332 E coli isolates, 13 (<1%) of 348 Klebsiella pneumoniae,

160 found in substantial proportions of neonatal E coli isolates, with no significant change from 2009 to

161 cted or colonized with ceftazidime-resistant E coli, K pneumoniae, or both were identified.

162 of clinical development-ie, enterotoxigenic E coli, Klebsiella pneumoniae, non-typhoidal Salmonella,

163 lly engineered) have intestinal expansion of E coli leading to visceral hypersensitivity.

164 ed resistance to immune clearance in an ESBL E coli lineage already known for its virulence is an uns

165 E coli LPS and human HSP 60 produced similar effects.

166 duction, but it did not alter the ability of E coli LPS to induce these functions.

167 assess the safety of heat-labile toxins from E coli (LT) delivered via patch.

168 gene expression in commensal gut bacterium (E coli NC101).

169 Here we utilize non-pathogenic E coli Nissle as a versatile platform for the developmen

170 The E coli O-antigen is a promising vaccine target.

171 Deletion of rpoS in E coli O104:H4 Deltastx2 and typical EAEC resulted in a

172 Here, we identified an E coli O104:H4 isolate that carried a single-nucleotide

173 ates that RpoS acts as a global repressor of E coli O104:H4 virulence, primarily through an AggR-depe

174 he evolution and geographical distibution of E coli O157 (and its close pathogenic relatives); the ma

175 Because E coli O157 can survive in the environment for more than

176 Many infections of E coli O157 could be prevented by the more effective app

177 food or beverage sources and the recovery of E coli O157 from the rafters suggest that airborne dispe

178 Case-patients had laboratory-confirmed E coli O157 infection, hemolytic-uremic syndrome, or blo

179 Environmental contamination with E coli O157 may be a public health problem.

180 d 42 weeks after the fair also grew the same E coli O157 strain.

181 ks after the fair grew Shiga toxin-producing E coli O157.

182 Deer can be colonized by E coli O157:H7 and can be a source of human infections.

183 ly determine whether antibiotic treatment of E coli O157:H7 enteritis increases the risk of HUS.

184 eported a series of patients with documented E coli O157:H7 enteritis, some of whom developed HUS; ha

185 sed risk of HUS with antibiotic treatment of E coli O157:H7 enteritis.

186 ate power, with multiple distinct strains of E coli O157:H7 represented, is needed to conclusively de

187 In a subsequent survey, E coli O157:H7 was recovered from 3 (9%) of 32 deer feca

188 E coli O157:H7 with the same distinctive, pulsed-field g

189 We further tested 33 isolates of E coli O157:H7, STEC, Shigella dysenteriae, and nonpatho

190 cherichia coli, in North America principally E coli O157:H7.

191 However, significantly fewer UTIs caused by E coli of any serotype were noted in the vaccine group c

192 sors such as DTT, IFN, and adherent-invasive E coli or control agents; cells were analyzed by immunob

193 A virus infection from patients with either E coli or S pneumoniae infection.

194 uch as enteroaggregative or enteropathogenic E coli or Salmonella).

195 s those produced by Shigella, enteroinvasive E coli, or Clostridium difficile) that damage cells or t

196 ent set of patients with either influenza A, E coli, or S pneumoniae infection.

197 We conclude that FMT contributes to pks(+)E coli persistence or eradication in patients with rCDI

198 This was a longitudinal, E coli population, genomic, cohort study that sampled is

199 We sequenced all E coli positive blood samples from the two adult haemato

200 mmunogenic than the native Escherichia coli (E coli) preparation, and can be more feasibly administer

201 lations with either Staphylococcus aureus or E coli, pretreatment with mAb LAM1.3 did not significant

202 e numbers of human infections caused by ESBL-E coli; prevention of the spread of resistant lineages a

203 ts were colonized with ceftazidime-resistant E coli; prior receipt of ciprofloxacin or trimethoprim-s

204 Enterotoxigenic E coli producing heat-stable toxin among children aged 1

205 ing rotavirus, Shigella spp, enterotoxigenic E coli producing heat-stable toxin, and Cryptosporidium

206 ence of all five known c-type cytochromes in E coli, providing biochemical evidence that these are cc

207 e plasmid carrying mcr-1 was mobilised to an E coli recipient at a frequency of 10(-1) to 10(-3) cell

208 Biliary E coli resembled commensals (phylogroup distribution, se

209 ransferase enzyme family, with expression in E coli resulting in the addition of phosphoethanolamine

210 scherichia coli, heat-stable enterotoxigenic E coli, rotavirus, Shigella spp and enteroinvasive E col

211 301 K pneumoniae samples and 77 (19%) of 402 E coli samples were carbapenemase (KPC, NDM, OXA-48-like

212 ial population (90 sequence types) and mixed E coli sequence type carriage.

213 data, we assembled a global dataset of 9001 E coli sequences from five publicly available data colle

214 te vaccine containing the O-antigens of four E coli serotypes (ExPEC4V).

215 ncoding heat-stable toxin, enteroaggregative E coli, Shigella spp (non-dysentery cases), Aeromonas sp

216 C binding to EPCR plus sublethal numbers of E coli (SLEC) (n = 4); (2) mAb to EPCR that does not blo

217 imes), and heat-stable enterotoxin-producing E coli ([ST-ETEC] around 1.5 times).

218 fy microbiome and resistome perturbation and E coli strain acquisition associated with travel.

219 The mcr-1 gene in E coli strain SHP45 was identified by whole plasmid sequ

220 When an E coli strain, SHP45, possessing colistin resistance tha

221 variation have focused on laboratory-adapted E coli strains and have been limited in the number of mu

222 ioral screens on a genome-wide collection of E coli strains identified 22 metabolic mutants that indu

223 cteristics) and the number of ESBL-producing E coli strains isolated from urine samples of individual

224 immunogenicity of ETVAX, consisting of four E coli strains overexpressing the most prevalent colonis

225 s with and without a phenotype in three K-12 E coli strains using multiple single-stranded oligonucle

226 data show that endogenous DNA gap repair in E coli supports efficient multiplex site-directed mutage

227 The cell-free E coli system offers a platform for rapidly generating i

228 entify the most important reservoirs of ESBL-E coli that colonise and infect humans to identify strat

229 athways may be relevant to understanding why E coli that express Stx2 are more likely to cause D(+)HU

230 ad stool samples positive for ESBL-producing E coli, the most common of which was associated with bla

231 ators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse eve

232 Here we report the crystal structures of E coli transcription initiation complexes (TICs) contain

233 A genetic threshold to infer E coli transmission was defined by maximum within-host s

234 ith the occurence of community-acquired ESBL E coli UTI.

235 number of community-acquired ESBL-producing E coli UTIs in each department was positively associated

236 number of community-acquired ESBL-producing E coli UTIs.

237 tested an oral, inactivated, enterotoxigenic E coli vaccine (ETVAX), which has been previously shown

238 onality, and the incidence of UTIs caused by E coli vaccine serotypes in each group.

239 of dominant colibactin-producing lineages of E coli varies considerably across geographical regions.

240 ferent signature discriminated patients with E coli versus S aureus infections with 85% accuracy (34

241 The ratio of K pneumoniae to E coli was 11:1.

242 ories, the mean prevalence of ESBL-producing E coli was 3.0% (range, 1.4%-8.8%).

243 al inflammatory reaction to inoculation with E coli was attenuated, as quantified by changes in blood

244 Sampling for ESBL-E coli was done between Aug 1, 2013, and Dec 15, 2014.

245 sia were decreased in all 3 studies, whereas E coli was increased in 4 of 9 studies.

246 ony-forming units per mL of vaccine-serotype E coli was noted in the vaccine compared with the placeb

247 tion and discrimination between S aureus and E coli was possible using a combination of [11C]PABA and

248 Consecutive clinical isolates of E coli were collected at the Royal London Hospital in 19

249 cts, although apoptotic effects of opsonized E coli were greater.

250 E coli were isolated from 485 samples collected from wil

251 We found high diversity of ESBL-producing E coli, with 170 sequence types and 166 genomic clusters